Chafic Karam, MD
Neurology
Accepting new patients
Sees patients age 18 and up
Penn Neuroscience Center - Neurology
Headshot of Chafic Karam, MD
Penn Medicine Provider

About me

  • Chief, Neuromuscular Division
  • Professor of Clinical Neurology

Education and training

  • Medical School: Saint Joseph's University
  • Residency: Hotel Dieu de France
  • Residency: Mount Sinai Hospital
  • Residency: Mass General Brigham Healthcare Center - Chestnut Hill
  • Residency: Mayo Clinic

What my patients think about me

Average Rating

207 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
April 2026
great communication skills
Anonymous
April 2026
i thought he was thorough, took me seriously, cared
Anonymous
March 2026
he's pro-active and made a point of saying good bye to me before hustling off to a meeting.
Anonymous
March 2026
very thoughtful feedback and options provided.

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Karam is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Donofrio PD, Gorson KC, Hofman E, Karam C, Kira JI, Kostera-Pruszczyk A, Léger JM, Nobile-Orazio E, Attarian S, Markov M, Tse A, De Roeck A, Lewis RA. Diagnostic adjudication of potential participants with chronic inflammatory demyelinating polyradiculoneuropathy in the ADHERE trial of subcutaneous efgartigimod PH20 , J Neurol Sci. : 2026


John E. Dvorak, Sami Khella, Brian Drachman, Rebecca Row, Janice Pieretti, Hansie Mathelier, Chafic Karam Prevalence and attribution of polyneuropathy in p.V142I (V122I) hereditary transthyretin amyloidosis , Journal of the Neurological Sciences: 2026


Joban Vaishnav, Dimitrios Bampatsias, Brian C. Boursiquot, Yevgeniy Brailovsky, Kristin Hsu, Jamie Zigterman, Rajshekhar Chakraborty, Ashutosh Wechalekar, Pablo Garcia Pavia, Ronald Witteles, Mazen Hanna, Chafic Karam, Mathew S. Maurer, and Jan M. Griffin Disease Prognosis and Progression in Transthyretin Amyloidosis: JACC: CardioOncology State-of-the-Art Review , JACC: CardioOncology , 8(2): 2026


Karam C. Clinical Utility of Serum Neurofilament Light Chain in Peripheral Neuropathy. , Muscle Nerve. : 2026,73(1):86-92.


Chakraborty R, Brailovsky Y, Hanna M, Witteles R, Vaishnav J, Hoffman JE, Griffin JM, Garcia-Pavia P, Wolinsky D, Karam C, Lachmann HJ, Gertz MA, Boursiquot BC, Bampatsias D, Hsu K, Johnson PT, Zigterman JL, Kazemzadeh AC, Maurer MS, Wechalekar AD. Prognostic Factors and Progression Biomarkers in AL Amyloidosis: Mapping Current Knowledge and Critical Gaps , Blood. 2026 Mar 4:blood.2025031651.: 2026


Fedak RR, Ruggerie RN, Shan Y, Curvino EJ, de Sousa JF, Daniel S, Ngo-Casi M, Kamboh H, Vu T, Durmuş H, Mozaffar T, Howard JF Jr, English EP, Benson A, Duvernay MT, Singer MS, Kalayoglu MV, Brunn C, Bodansky A, Anderson MS, DeRisi JL, Garcia ST, Yu DJL, Zorn KC, Kurtoglu M, Miljković MD, Stewart CA, Jewell CM; MG-001 Study Team. BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial , Nat Med: 2026


Vu T, Durmus H, Rivner M, Shroff S, Ragole T, Myers B, Pasnoor M, Small G, Karam C, Vullaganti M, Peltier A, Sahagian G, Feinberg MH, Slanksy A, Barnett-Tapia C, Siddiqi Z, Gwathmey K, Badruddoja MA, Kamboh H, Ruggerie RN, Fedak RR, Stewart CA, Kurtoglu M, Kalayoglu M, Singer M, Jewell CM, Miljkovic MD, Dimachkie M, Mozaffar T, Howard JF Jr; MG-001 Study Team. BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial , Nat Med. : 2026


Blein C, Karam C, Arvin-Berod C, Gelinas D, Barrera-Sierra S, Syed HUTA, Ward C, Goyal A, Guptill J. Real-world treatment utilization in adults with chronic inflammatory demyelinating polyneuropathy in the United States. , Front Neurol. 2026 Jan 29;16:1726857: 2026


Singh A, Wyatt J, Théaudin M, Karam C, Kasper D, Streubel B, Frascello K, Bondue A. Effectiveness and Utility of Genetic Testing in Establishing a Diagnosis of Hereditary Transthyretin Amyloidosis , Journal of Clinical Medicine.: 2025


Khandelwal N, Sanchirico M, Ajibade A, Munshi K, Vu M, Engel-Nitz N, Steiger C, Anderson AJ, Karam C. Characteristics, Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients with Multifocal Motor Neuropathy: A US Claims Database Cohort Study , J Health Econ Outcomes Res. 2025 Jun 26;12(1):261-268. : 2025


View all publications